The date of discovery may be related to when the link between the drug and the condition was established
Another study found that patients with type 2 diabetes and kidney disease who were prescribed GLP-1s had a 39% higher risk of requiring kidney replacement therapy (dialysis or transplant), compared to patients taking SGLT2 inhibitors
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Abuirmeileh et al., 2012) with great success culminating now with clinical trials
Hanif M, Hays AG, Nagarajan JS, Sah SP, Weinstock RS, Taub CC
Marso SP, Daniels GH, Brown-Frandsen K, et al